Neuropathic Pain - Pipeline Review, H2 2015

Date: December 31, 2015
Pages: 602
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: N8DC6078A19EN
Leaflet:

Download PDF Leaflet

Neuropathic Pain - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Neuropathic Pain - Pipeline Review, H2 2015’, provides an overview of the Neuropathic Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuropathic Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Neuropathic Pain and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Neuropathic Pain pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Neuropathic Pain Overview
Therapeutics Development
Neuropathic Pain - Therapeutics under Development by Companies
Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes
Neuropathic Pain - Pipeline Products Glance
Neuropathic Pain - Products under Development by Companies
Neuropathic Pain - Products under Investigation by Universities/Institutes
Neuropathic Pain - Companies Involved in Therapeutics Development
Neuropathic Pain - Therapeutics Assessment
Drug Profiles
Neuropathic Pain - Recent Pipeline Updates
Neuropathic Pain - Dormant Projects
Neuropathic Pain - Discontinued Products
Neuropathic Pain - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Neuropathic Pain, H2 2015
Number of Products under Development for Neuropathic Pain - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd..1)
Number of Products under Development by Companies, H2 2015 (Contd..2)
Number of Products under Development by Companies, H2 2015 (Contd..3)
Number of Products under Development by Companies, H2 2015 (Contd..4)
Number of Products under Development by Companies, H2 2015 (Contd..5)
Number of Products under Development by Companies, H2 2015 (Contd..6)
Number of Products under Development by Companies, H2 2015 (Contd..7)
Number of Products under Development by Companies, H2 2015 (Contd..8)
Number of Products under Development by Companies, H2 2015 (Contd..9)
Number of Products under Development by Companies, H2 2015 (Contd..10)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Products under Development by Companies, H2 2015 (Contd..4)
Products under Development by Companies, H2 2015 (Contd..5)
Products under Development by Companies, H2 2015 (Contd..6)
Products under Development by Companies, H2 2015 (Contd..7)
Products under Development by Companies, H2 2015 (Contd..8)
Products under Development by Companies, H2 2015 (Contd..9)
Products under Development by Companies, H2 2015 (Contd..10)
Products under Development by Companies, H2 2015 (Contd..11)
Products under Development by Companies, H2 2015 (Contd..12)
Products under Development by Companies, H2 2015 (Contd..13)
Products under Investigation by Universities/Institutes, H2 2015
Products under Investigation by Universities/Institutes, H2 2015 (Contd..1)
Neuropathic Pain - Pipeline by 2-BBB Medicines BV, H2 2015
Neuropathic Pain - Pipeline by AbbVie Inc., H2 2015
Neuropathic Pain - Pipeline by Advinus Therapeutics Ltd., H2 2015
Neuropathic Pain - Pipeline by Adynxx, Inc., H2 2015
Neuropathic Pain - Pipeline by Aestus Therapeutics, Inc., H2 2015
Neuropathic Pain - Pipeline by Affectis Pharmaceuticals AG, H2 2015
Neuropathic Pain - Pipeline by Allergan Plc, H2 2015
Neuropathic Pain - Pipeline by Amura Holdings Limited, H2 2015
Neuropathic Pain - Pipeline by AnaBios Corporation, H2 2015
Neuropathic Pain - Pipeline by Anavex Life Sciences Corp., H2 2015
Neuropathic Pain - Pipeline by AngioChem Inc., H2 2015
Neuropathic Pain - Pipeline by Asahi Kasei Pharma Corp., H2 2015
Neuropathic Pain - Pipeline by Astellas Pharma Inc., H2 2015
Neuropathic Pain - Pipeline by AstraZeneca Plc, H2 2015
Neuropathic Pain - Pipeline by BCN Peptides, S.A., H2 2015
Neuropathic Pain - Pipeline by Benitec Biopharma Limited, H2 2015
Neuropathic Pain - Pipeline by BioDelivery Sciences International, Inc., H2 2015
Neuropathic Pain - Pipeline by BioLineRx, Ltd., H2 2015
Neuropathic Pain - Pipeline by Biomar Microbial Technologies, H2 2015
Neuropathic Pain - Pipeline by Bionomics Limited, H2 2015
Neuropathic Pain - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2015
Neuropathic Pain - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Neuropathic Pain - Pipeline by Bristol-Myers Squibb Company, H2 2015
Neuropathic Pain - Pipeline by Can-Fite BioPharma Ltd., H2 2015
Neuropathic Pain - Pipeline by Cara Therapeutics, Inc., H2 2015
Neuropathic Pain - Pipeline by Catalyst Biosciences, Inc., H2 2015
Neuropathic Pain - Pipeline by Cavion LLC, H2 2015
Neuropathic Pain - Pipeline by Cerecor Inc., H2 2015
Neuropathic Pain - Pipeline by Circuit Therapeutics, Inc., H2 2015
Neuropathic Pain - Pipeline by CLL Pharma, H2 2015
Neuropathic Pain - Pipeline by Colby Pharmaceutical Company, H2 2015
Neuropathic Pain - Pipeline by Convergence Pharmaceuticals Ltd., H2 2015
Neuropathic Pain - Pipeline by Creabilis SA, H2 2015
Neuropathic Pain - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2015
Neuropathic Pain - Pipeline by Cytogel Pharma, LLC, H2 2015
Neuropathic Pain - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
Neuropathic Pain - Pipeline by Daiichi Sankyo Company, Limited, H2 2015
Neuropathic Pain - Pipeline by DermaXon, LLC, H2 2015
Neuropathic Pain - Pipeline by Develco Pharma Schweiz AG, H2 2015
Neuropathic Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2015
Neuropathic Pain - Pipeline by Dong-A Socio Group, H2 2015
Neuropathic Pain - Pipeline by Eisai Co., Ltd., H2 2015
Neuropathic Pain - Pipeline by Eli Lilly and Company, H2 2015
Neuropathic Pain - Pipeline by Endece, LLC, H2 2015
Neuropathic Pain - Pipeline by Evotec AG, H2 2015
Neuropathic Pain - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Neuropathic Pain - Pipeline by Genecode AS, H2 2015
Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2015
Neuropathic Pain - Pipeline by Glialogix, Inc., H2 2015
Neuropathic Pain - Pipeline by Grunenthal GmbH, H2 2015
Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H2 2015
Neuropathic Pain - Pipeline by Hydra Biosciences, Inc., H2 2015
Neuropathic Pain - Pipeline by Immune Pharmaceuticals Inc., H2 2015
Neuropathic Pain - Pipeline by Integral Molecular, Inc., H2 2015
Neuropathic Pain - Pipeline by IntelGenx Corp., H2 2015
Neuropathic Pain - Pipeline by Intellipharmaceutics International Inc., H2 2015
Neuropathic Pain - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015
Neuropathic Pain - Pipeline by Johnson & Johnson, H2 2015
Neuropathic Pain - Pipeline by Kareus Therapeutics, SA, H2 2015
Neuropathic Pain - Pipeline by Kineta, Inc., H2 2015
Neuropathic Pain - Pipeline by Knopp Biosciences LLC, H2 2015
Neuropathic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2015
Neuropathic Pain - Pipeline by LEO Pharma A/S, H2 2015
Neuropathic Pain - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2015
Neuropathic Pain - Pipeline by Lipopharma Therapeutics SL, H2 2015
Neuropathic Pain - Pipeline by Lohocla Research Corporation, H2 2015
Neuropathic Pain - Pipeline by Lpath, Inc., H2 2015
Neuropathic Pain - Pipeline by Mapi Pharma Ltd., H2 2015
Neuropathic Pain - Pipeline by Medy-Tox Inc., H2 2015
Neuropathic Pain - Pipeline by Merck & Co., Inc., H2 2015
Neuropathic Pain - Pipeline by Mertiva AB, H2 2015
Neuropathic Pain - Pipeline by Metys Pharmaceuticals AG, H2 2015
Neuropathic Pain - Pipeline by Nanomerics Ltd, H2 2015
Neuropathic Pain - Pipeline by Nektar Therapeutics, H2 2015
Neuropathic Pain - Pipeline by Neurim Pharmaceuticals Ltd, H2 2015
Neuropathic Pain - Pipeline by Neurocentrx Pharma Ltd., H2 2015
Neuropathic Pain - Pipeline by Neurodyn Inc., H2 2015
Neuropathic Pain - Pipeline by NeurOp, Inc, H2 2015
Neuropathic Pain - Pipeline by Newron Pharmaceuticals S.p.A., H2 2015
Neuropathic Pain - Pipeline by Nippon Chemiphar Co., Ltd., H2 2015
Neuropathic Pain - Pipeline by NoNO, Inc., H2 2015
Neuropathic Pain - Pipeline by Novaremed, H2 2015
Neuropathic Pain - Pipeline by NsGene A/S, H2 2015
Neuropathic Pain - Pipeline by Nuvo Research Inc., H2 2015
Neuropathic Pain - Pipeline by Orion Oyj, H2 2015
Neuropathic Pain - Pipeline by Pfizer Inc., H2 2015
Neuropathic Pain - Pipeline by Pharmaleads , H2 2015
Neuropathic Pain - Pipeline by PharmEste, H2 2015
Neuropathic Pain - Pipeline by Phosphagenics Limited, H2 2015
Neuropathic Pain - Pipeline by Prismic Pharmaceuticals, Inc., H2 2015
Neuropathic Pain - Pipeline by Protagonist Therapeutics Inc., H2 2015
Neuropathic Pain - Pipeline by PsychoGenics, Inc., H2 2015
Neuropathic Pain - Pipeline by Purdue Pharma L.P., H2 2015
Neuropathic Pain - Pipeline by RaQualia Pharma Inc., H2 2015
Neuropathic Pain - Pipeline by Re-Pharm Limited, H2 2015
Neuropathic Pain - Pipeline by Recro Pharma, Inc., H2 2015
Neuropathic Pain - Pipeline by Relmada Therapeutics, Inc., H2 2015
Neuropathic Pain - Pipeline by Revance Therapeutics, Inc., H2 2015
Neuropathic Pain - Pipeline by Rottapharm SpA, H2 2015
Neuropathic Pain - Pipeline by Saniona AB, H2 2015
Neuropathic Pain - Pipeline by Scilex Pharmaceuticals, Inc., H2 2015
Neuropathic Pain - Pipeline by Shionogi & Co., Ltd., H2 2015
Neuropathic Pain - Pipeline by Sigma-Tau S.p.A., H2 2015
Neuropathic Pain - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015
Neuropathic Pain - Pipeline by Sova Pharmaceuticals, Inc., H2 2015
Neuropathic Pain - Pipeline by Sphaera Pharma Pvt. Ltd., H2 2015
Neuropathic Pain - Pipeline by Spinifex Pharmaceuticals Pty Limited, H2 2015
Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc., H2 2015
Neuropathic Pain - Pipeline by Syntrix Biosystems, Inc., H2 2015
Neuropathic Pain - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015
Neuropathic Pain - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Neuropathic Pain - Pipeline by Theranexus SAS, H2 2015
Neuropathic Pain - Pipeline by Theravasc, Inc., H2 2015
Neuropathic Pain - Pipeline by Toray Industries, Inc., H2 2015
Neuropathic Pain - Pipeline by Torrent Pharmaceuticals Limited, H2 2015
Neuropathic Pain - Pipeline by Trevena, Inc., H2 2015
Neuropathic Pain - Pipeline by Trigemina, Inc., H2 2015
Neuropathic Pain - Pipeline by Vichem Chemie Research Ltd., H2 2015
Neuropathic Pain - Pipeline by Virobay Inc., H2 2015
Neuropathic Pain - Pipeline by VistaGen Therapeutics , Inc., H2 2015
Neuropathic Pain - Pipeline by WEX Pharmaceuticals Inc., H2 2015
Neuropathic Pain - Pipeline by Winston Pharmaceuticals, Inc., H2 2015
Neuropathic Pain - Pipeline by Yungjin Pharm. Co., Ltd., H2 2015
Neuropathic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Neuropathic Pain Therapeutics - Recent Pipeline Updates, H2 2015
Neuropathic Pain - Dormant Projects, H2 2015
Neuropathic Pain - Dormant Projects (Contd..1), H2 2015
Neuropathic Pain - Dormant Projects (Contd..2), H2 2015
Neuropathic Pain - Dormant Projects (Contd..3), H2 2015
Neuropathic Pain - Dormant Projects (Contd..4), H2 2015
Neuropathic Pain - Dormant Projects (Contd..5), H2 2015
Neuropathic Pain - Dormant Projects (Contd..6), H2 2015
Neuropathic Pain - Dormant Projects (Contd..7), H2 2015
Neuropathic Pain - Dormant Projects (Contd..8), H2 2015
Neuropathic Pain - Dormant Projects (Contd..9), H2 2015
Neuropathic Pain - Dormant Projects (Contd..10), H2 2015
Neuropathic Pain - Dormant Projects (Contd..11), H2 2015
Neuropathic Pain - Dormant Projects (Contd..12), H2 2015
Neuropathic Pain - Dormant Projects (Contd..13), H2 2015
Neuropathic Pain - Dormant Projects (Contd..14), H2 2015
Neuropathic Pain - Dormant Projects (Contd..15), H2 2015
Neuropathic Pain - Dormant Projects (Contd..16), H2 2015
Neuropathic Pain - Dormant Projects (Contd..17), H2 2015
Neuropathic Pain - Dormant Projects (Contd..18), H2 2015
Neuropathic Pain - Dormant Projects (Contd..19), H2 2015
Neuropathic Pain - Dormant Projects (Contd..20), H2 2015
Neuropathic Pain - Discontinued Products, H2 2015
Neuropathic Pain - Discontinued Products (Contd..1), H2 2015
Neuropathic Pain - Discontinued Products (Contd..2), H2 2015
Neuropathic Pain - Discontinued Products (Contd..3), H2 2015
Neuropathic Pain - Discontinued Products (Contd..4), H2 2015
Neuropathic Pain - Discontinued Products (Contd..5), H2 2015
Neuropathic Pain - Discontinued Products (Contd..6), H2 2015
Neuropathic Pain - Discontinued Products (Contd..7), H2 2015

LIST OF FIGURES

Number of Products under Development for Neuropathic Pain, H2 2015
Number of Products under Development for Neuropathic Pain - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

2-BBB Medicines BV
AbbVie Inc.
Advinus Therapeutics Ltd.
Adynxx, Inc.
Aestus Therapeutics, Inc.
Affectis Pharmaceuticals AG
Allergan Plc
Amura Holdings Limited
AnaBios Corporation
Anavex Life Sciences Corp.
AngioChem Inc.
Asahi Kasei Pharma Corp.
Astellas Pharma Inc.
AstraZeneca Plc
BCN Peptides, S.A.
Benitec Biopharma Limited
BioDelivery Sciences International, Inc.
BioLineRx, Ltd.
Biomar Microbial Technologies
Bionomics Limited
Biscayne Pharmaceuticals, Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Can-Fite BioPharma Ltd.
Cara Therapeutics, Inc.
Catalyst Biosciences, Inc.
Cavion LLC
Cerecor Inc.
Circuit Therapeutics, Inc.
CLL Pharma
Colby Pharmaceutical Company
Convergence Pharmaceuticals Ltd.
Creabilis SA
Crinetics Pharmaceuticals, Inc.
Cytogel Pharma, LLC
Daewoong Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
DermaXon, LLC
Develco Pharma Schweiz AG
Dompe Farmaceutici S.p.A.
Dong-A Socio Group
Eisai Co., Ltd.
Eli Lilly and Company
Endece, LLC
Evotec AG
F. Hoffmann-La Roche Ltd.
Genecode AS
Glenmark Pharmaceuticals Ltd.
Glialogix, Inc.
Grunenthal GmbH
GW Pharmaceuticals Plc
Hydra Biosciences, Inc.
Immune Pharmaceuticals Inc.
Integral Molecular, Inc.
IntelGenx Corp.
Intellipharmaceutics International Inc.
Jeil Pharmaceutical Co., Ltd.
Johnson & Johnson
Kareus Therapeutics, SA
Kineta, Inc.
Knopp Biosciences LLC
Laboratorios Del Dr. Esteve S.A.
LEO Pharma A/S
Lexicon Pharmaceuticals, Inc.
Lipopharma Therapeutics SL
Lohocla Research Corporation
Lpath, Inc.
Mapi Pharma Ltd.
Medy-Tox Inc.
Merck & Co., Inc.
Mertiva AB
Metys Pharmaceuticals AG
Nanomerics Ltd
Nektar Therapeutics
Neurim Pharmaceuticals Ltd
Neurocentrx Pharma Ltd.
Neurodyn Inc.
NeurOp, Inc
Newron Pharmaceuticals S.p.A.
Nippon Chemiphar Co., Ltd.
NoNO, Inc.
Novaremed
NsGene A/S
Nuvo Research Inc.
Orion Oyj
Pfizer Inc.
Pharmaleads
PharmEste
Phosphagenics Limited
Prismic Pharmaceuticals, Inc.
Protagonist Therapeutics Inc.
PsychoGenics, Inc.
Purdue Pharma L.P.
RaQualia Pharma Inc.
Re-Pharm Limited
Recro Pharma, Inc.
Relmada Therapeutics, Inc.
Revance Therapeutics, Inc.
Rottapharm SpA
Saniona AB
Scilex Pharmaceuticals, Inc.
Shionogi & Co., Ltd.
Sigma-Tau S.p.A.
SK Biopharmaceuticals Co., Ltd.
Sova Pharmaceuticals, Inc.
Sphaera Pharma Pvt. Ltd.
Spinifex Pharmaceuticals Pty Limited
Sunovion Pharmaceuticals Inc.
Syntrix Biosystems, Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited
Theranexus SAS
Theravasc, Inc.
Toray Industries, Inc.
Torrent Pharmaceuticals Limited
Trevena, Inc.
Trigemina, Inc.
Vichem Chemie Research Ltd.
Virobay Inc.
VistaGen Therapeutics , Inc.
WEX Pharmaceuticals Inc.
Winston Pharmaceuticals, Inc.
Yungjin Pharm. Co., Ltd.
Zynerba Pharmaceuticals, Inc.
Skip to top


Visceral Pain - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 58 pages
Visceral Pain - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 64 pages
Ocular Pain - Pipeline Review, H2 2016 US$ 2,000.00 Aug, 2016 · 70 pages
Diabetic Neuropathic Pain - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
Peripheral Neuropathic Pain - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages

Ask Your Question

Neuropathic Pain - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: